• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脂质体累积于缺血心肌和保护心脏的能力与尺寸相关。

Size-Dependent Ability of Liposomes to Accumulate in the Ischemic Myocardium and Protect the Heart.

机构信息

Research Institute for Complex Issues of Cardiovascular Diseases, Siberian Branch of the Russian Academy of Medical Sciences (SB RAS), Laboratory of New Biomaterials, Kemerovo, Russia.

Ecology and Natural Resources, Institute of Biology, Kemerovo State University, Kemerovo, Russia.

出版信息

J Cardiovasc Pharmacol. 2018 Sep;72(3):143-152. doi: 10.1097/FJC.0000000000000606.

DOI:10.1097/FJC.0000000000000606
PMID:29927783
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6125753/
Abstract

Liposomes have the potential to be used for drug delivery. Meanwhile, liposome size may affect their accumulation in the target tissue. We investigated the myocardial accumulation of 2 populations of liposomes (∼70 and 110 nm diameter) during ischemia and their effect on ischemia/reperfusion injury. Isolated rat hearts were subjected to 30 minutes of low-flow ischemia with the liposomes, followed by 30 minutes of liposome-free reperfusion. The liposomes were loaded with the fluorescent dye Nile Red to assess their accumulation in the myocardium. The cardiac functional recovery during reperfusion was evaluated using force-velocity characteristics and coronary flow (CF). Reperfusion injury was evaluated by lactate dehydrogenase release. In addition, CF and contractility were assessed in hearts perfused normally with 70 nm liposomes. There was a 6- and 4-fold greater accumulation of the small liposomes in the myocardium and mitochondria, respectively, compared with the large liposomes. Importantly, even without any incorporated drugs, both populations of liposomes improved functional recovery and reduced lactate dehydrogenase release. However, the smaller liposomes showed significantly higher protective and vasodilatory effects during reperfusion than the larger particles. These liposomes also increased CF and contractility during normal perfusion. We suggest that the protective properties of the liposomes could be related to their membrane-stabilizing effect.

摘要

脂质体具有作为药物传递载体的潜力。同时,脂质体的大小可能会影响它们在靶组织中的积累。我们研究了两种脂质体(直径约 70 和 110nm)在缺血期间的心肌积累及其对缺血/再灌注损伤的影响。分离的大鼠心脏在脂质体存在下经历 30 分钟的低流量缺血,随后进行 30 分钟无脂质体再灌注。脂质体用荧光染料尼罗红负载,以评估其在心肌中的积累。用力-速度特性和冠状动脉流量(CF)评估再灌注期间的心脏功能恢复。通过乳酸脱氢酶释放评估再灌注损伤。此外,还评估了用 70nm 脂质体正常灌注的心脏中的 CF 和收缩性。与大脂质体相比,小脂质体在心和线粒体中的积累分别增加了 6 倍和 4 倍。重要的是,即使没有任何掺入的药物,两种脂质体都能改善功能恢复并减少乳酸脱氢酶的释放。然而,与较大颗粒相比,较小的脂质体在再灌注期间表现出更高的保护和血管舒张作用。这些脂质体还增加了正常灌注期间的 CF 和收缩性。我们认为,脂质体的保护特性可能与其膜稳定作用有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b18/6125753/09add11a7749/jcvp-72-143-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b18/6125753/af54aea4758e/jcvp-72-143-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b18/6125753/5459b281b082/jcvp-72-143-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b18/6125753/b79e6fe328ff/jcvp-72-143-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b18/6125753/09a106cc7236/jcvp-72-143-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b18/6125753/c2ea8dc0ffe6/jcvp-72-143-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b18/6125753/06234ee32f8a/jcvp-72-143-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b18/6125753/09add11a7749/jcvp-72-143-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b18/6125753/af54aea4758e/jcvp-72-143-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b18/6125753/5459b281b082/jcvp-72-143-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b18/6125753/b79e6fe328ff/jcvp-72-143-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b18/6125753/09a106cc7236/jcvp-72-143-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b18/6125753/c2ea8dc0ffe6/jcvp-72-143-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b18/6125753/06234ee32f8a/jcvp-72-143-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b18/6125753/09add11a7749/jcvp-72-143-g008.jpg

相似文献

1
Size-Dependent Ability of Liposomes to Accumulate in the Ischemic Myocardium and Protect the Heart.脂质体累积于缺血心肌和保护心脏的能力与尺寸相关。
J Cardiovasc Pharmacol. 2018 Sep;72(3):143-152. doi: 10.1097/FJC.0000000000000606.
2
Melatonin protects against heart ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening.褪黑素通过抑制线粒体通透性转换孔开放来保护心脏免受缺血再灌注损伤。
Am J Physiol Heart Circ Physiol. 2009 Oct;297(4):H1487-93. doi: 10.1152/ajpheart.00163.2009. Epub 2009 Aug 14.
3
Experimental conditions determine effects of ascorbic acid on reperfusion injury: comparison of tissue damage with hemodynamic parameters in rat isolated hearts.实验条件决定了抗坏血酸对再灌注损伤的影响:大鼠离体心脏组织损伤与血流动力学参数的比较
Methods Find Exp Clin Pharmacol. 1992 Jul-Aug;14(6):419-30.
4
Isoespintanol, a monoterpene isolated from oxandra cf xylopioides, ameliorates the myocardial ischemia-reperfusion injury by AKT/PKCε/eNOS-dependent pathways.异缬草醇,一种从 Oxandra cf xylopioides 中分离得到的单萜,通过 AKT/PKCε/eNOS 依赖性途径改善心肌缺血再灌注损伤。
Naunyn Schmiedebergs Arch Pharmacol. 2020 Apr;393(4):629-638. doi: 10.1007/s00210-019-01761-9. Epub 2019 Nov 27.
5
Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function.在 P2Y 受体拮抗剂治疗的大鼠中,再灌注时给予 VX-765 抑制半胱天冬酶-1,可长期减少心肌梗死面积并保护心室功能。
Basic Res Cardiol. 2018 Jul 10;113(5):32. doi: 10.1007/s00395-018-0692-z.
6
Protease-activated receptor 2-mediated protection of myocardial ischemia-reperfusion injury: role of transient receptor potential vanilloid receptors.蛋白酶激活受体2介导的心肌缺血再灌注损伤保护作用:瞬时受体电位香草酸受体的作用
Am J Physiol Regul Integr Comp Physiol. 2009 Dec;297(6):R1681-90. doi: 10.1152/ajpregu.90746.2008. Epub 2009 Oct 7.
7
Tongmai formula improves cardiac function via regulating mitochondrial quality control in the myocardium with ischemia/reperfusion injury.通脉方通过调节心肌缺血/再灌注损伤中线粒体的质量控制来改善心脏功能。
Biomed Pharmacother. 2020 Dec;132:110897. doi: 10.1016/j.biopha.2020.110897. Epub 2020 Oct 28.
8
The radical trap 5,5-dimethyl-1-pyrroline N-oxide exerts dose-dependent protection against myocardial ischemia-reperfusion injury through preservation of mitochondrial electron transport.自由基捕获剂5,5-二甲基-1-吡咯啉N-氧化物通过维持线粒体电子传递对心肌缺血再灌注损伤发挥剂量依赖性保护作用。
J Pharmacol Exp Ther. 2009 May;329(2):515-23. doi: 10.1124/jpet.108.143479. Epub 2009 Feb 6.
9
Temperature preconditioning of isolated rat hearts--a potent cardioprotective mechanism involving a reduction in oxidative stress and inhibition of the mitochondrial permeability transition pore.离体大鼠心脏的温度预处理——一种强大的心脏保护机制,涉及氧化应激的降低和线粒体通透性转换孔的抑制。
J Physiol. 2007 Jun 15;581(Pt 3):1147-61. doi: 10.1113/jphysiol.2007.130369. Epub 2007 Mar 29.
10
A novel water-soluble and cell-permeable calpain inhibitor protects myocardial and mitochondrial function in postischemic reperfusion.一种新型水溶性且可穿透细胞的钙蛋白酶抑制剂可保护缺血再灌注后的心肌和线粒体功能。
Biol Chem. 2003 Dec;384(12):1597-603. doi: 10.1515/BC.2003.177.

引用本文的文献

1
Innovations in Cancer Therapy: Endogenous Stimuli-Responsive Liposomes as Advanced Nanocarriers.癌症治疗的创新:内源性刺激响应脂质体作为先进的纳米载体
Pharmaceutics. 2025 Feb 13;17(2):245. doi: 10.3390/pharmaceutics17020245.
2
Organic Nanoparticles in Progressing Cardiovascular Disease Treatment and Diagnosis.有机纳米颗粒在心血管疾病治疗与诊断进展中的应用
Polymers (Basel). 2024 May 16;16(10):1421. doi: 10.3390/polym16101421.
3
A bibliometric analysis of myocardial ischemia/reperfusion injury from 2000 to 2023.2000年至2023年心肌缺血/再灌注损伤的文献计量分析。

本文引用的文献

1
Nanomedicine applied to cardiovascular diseases: latest developments.应用于心血管疾病的纳米医学:最新进展
Ther Adv Cardiovasc Dis. 2017 Apr;11(4):133-142. doi: 10.1177/1753944717692293. Epub 2017 Feb 15.
2
Distribution of Systemically Administered Nanoparticles Reveals a Size-Dependent Effect Immediately following Cardiac Ischaemia-Reperfusion Injury.全身给药的纳米颗粒分布显示,在心脏缺血再灌注损伤后立即呈现出大小依赖性效应。
Sci Rep. 2016 May 10;6:25613. doi: 10.1038/srep25613.
3
Intracellular delivery of nanocarriers and targeting to subcellular organelles.
Front Cardiovasc Med. 2023 Jun 13;10:1180792. doi: 10.3389/fcvm.2023.1180792. eCollection 2023.
4
Intravascular Imaging of Atherosclerosis by Using Engineered Nanoparticles.利用工程纳米颗粒进行动脉粥样硬化的血管内成像。
Biosensors (Basel). 2023 Feb 24;13(3):319. doi: 10.3390/bios13030319.
5
Three-dimensional, symmetrically assembled microfluidic device for lipid nanoparticle production.用于脂质纳米颗粒生产的三维对称组装微流控装置。
RSC Adv. 2021 Jan 5;11(3):1430-1439. doi: 10.1039/d0ra08826a. eCollection 2021 Jan 4.
6
Vascular permeability in chronic rhinosinusitis enhances accumulation and retention of nanoscale pegylated liposomes.慢性鼻鼻窦炎中的血管通透性增强了纳米级聚乙二醇化脂质体的聚集和保留。
Nanomedicine. 2021 Nov;38:102453. doi: 10.1016/j.nano.2021.102453. Epub 2021 Aug 4.
7
Evaluation of the In Vitro Cytotoxic Activity of Caffeic Acid Derivatives and Liposomal Formulation against Pancreatic Cancer Cell Lines.咖啡酸衍生物及脂质体制剂对胰腺癌细胞系的体外细胞毒性活性评估
Materials (Basel). 2020 Dec 19;13(24):5813. doi: 10.3390/ma13245813.
纳米载体的细胞内递送及亚细胞细胞器靶向
Expert Opin Drug Deliv. 2016;13(1):49-70. doi: 10.1517/17425247.2015.1086745. Epub 2015 Sep 11.
4
Heart-targeted nanoscale drug delivery systems.靶向心脏的纳米药物递送系统。
J Biomed Nanotechnol. 2014 Sep;10(9):2038-62. doi: 10.1166/jbn.2014.1894.
5
Liposomes as nanomedical devices.作为纳米医疗设备的脂质体。
Int J Nanomedicine. 2015 Feb 2;10:975-99. doi: 10.2147/IJN.S68861. eCollection 2015.
6
Molecular strategies for targeting antioxidants to mitochondria: therapeutic implications.将抗氧化剂靶向线粒体的分子策略:治疗意义
Antioxid Redox Signal. 2015 Mar 10;22(8):686-729. doi: 10.1089/ars.2014.5952.
7
Mitochondria-targeted agents: Future perspectives of mitochondrial pharmaceutics in cardiovascular diseases.线粒体靶向药物:心血管疾病中线粒体药物治疗的未来展望。
World J Cardiol. 2014 Oct 26;6(10):1091-9. doi: 10.4330/wjc.v6.i10.1091.
8
Clinically-relevant consecutive treatment with isoproterenol and adenosine protects the failing heart against ischaemia and reperfusion.异丙肾上腺素和腺苷的临床相关连续治疗可保护衰竭心脏免受缺血和再灌注损伤。
J Transl Med. 2014 May 21;12:139. doi: 10.1186/1479-5876-12-139.
9
Nanomicellar carriers for targeted delivery of anticancer agents.用于靶向递送抗癌药物的纳米胶束载体。
Ther Deliv. 2014 Jan;5(1):53-68. doi: 10.4155/tde.13.135.
10
The physiology of cardiovascular disease and innovative liposomal platforms for therapy.心血管疾病的生理学与创新的脂质体治疗平台。
Int J Nanomedicine. 2013;8:629-40. doi: 10.2147/IJN.S30599. Epub 2013 Feb 9.